In a retrospective subanalysis of the CLARITY-TIMI 28 trial involving patients with STEMI, Gal-3 was associated with an increased risk of developing HF within 30 days post-myocardial infarction (OR 1.5 (95% CI: 1.24–1.82); p < 0.001) [29]. The gene discussed is LGALS3; the disease is myocardial infarction.